Cardiovascular risk in persons at risk of developing rheumatoid arthritis

• Published in: PloS one Vol. 15; no. 8; p. e0237072
• Main Authors: van Boheemen, Laurette, van Beers-Tas, Marian H, Kroese, Johanna M, van de Stadt, Lotte A, van Schaardenburg, Dirkjan, Nurmohamed, Michael T
• Format: Journal Article
• Language: English
• Published: San Francisco Public Library of Science 03-08-2020; Public Library of Science (PLoS)
• Subjects: Age; Angina pectoris; Antibodies; Antihypertensives; Apolipoproteins; Arthralgia; Arthritis; Autoantibodies; Autoimmune diseases; Biology and Life Sciences; Blood lipids; Blood pressure; Cardiovascular disease; Cardiovascular diseases; Cholesterol; Citrulline; Clinical medicine; Control methods; Coronary vessels; Demographics; Demography; Dentistry; Diagnosis; Ethnicity; Health aspects; Health risks; Heart diseases; Heart rate; High density lipoprotein; Immunology; Lipids; Lipoproteins (high density); Medicine and Health Sciences; Physiological aspects; Rheumatoid arthritis; Rheumatoid factor; Rheumatology; Risk analysis; Risk factors; Triglycerides; Netherlands
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0237072

Background Rheumatoid arthritis (RA) is associated with an increased cardiovascular disease (CVD) risk which may start even before diagnosis. To explore this CVD risk prior to RA, we determined multiple risk factors and two 10-year clinical risk scores in a cohort of individuals at-risk of RA. We also analyzed associations with arthritis development and autoantibody status and compared a subset of at-risk individuals to an age and sex matched seronegative control group. Methods In a cohort of 555 consecutive arthralgia patients positive for rheumatoid factor (RF) and / or anti-citrullinated protein antibody (ACPA) we retrospectively identified patients with preclinical arthritis (i.e. those who developed arthritis), and non-arthritis patients (those without arthritis development during maximum 5 years follow up). Demographics, CVD risk factors and the 10-year cardiovascular risk according to the SCORE and QRISK3 system were determined at baseline. Results Preclinical arthritis patients (n = 188) had a higher heart rate (68 vs 63 bpm, p = 0.048) and lower cholesterol (5.2 mmol/l vs 5.5, p = 0.006), HDL (1.0 mmol/l vs 1.1, p0.003) and ApoB (0.85 g/l vs 0.91, p = 0.011) compared to non-arthritis patients (n = 367). Lipid levels were associated with ACPA status in both the preclinical arthritis and non-arthritis group. Ten-year CVD risk scores did not differ between preclinical arthritis and non-arthritis patients, in total, 7% (SCORE) and 8% (QRISK3) of seropositive arthralgia patients were classified as high risk. Seropositive at-risk patients (n = 71) had higher total cholesterol (5.4 vs 4.9, p<0.001), TC/HDL ratio (4.0 vs 3.0, p<0.001), triglycerides (1.4 vs 1.0, p = 0.001), ApoB (1.0 vs 0.9, p = 0.019) and 10-year risk scores (median SCORE 1.0 vs 0.0, p = 0.030 and median QRISK3 4.4 vs 3.1, p<0.001) compared to seronegative controls. Conclusion Our results suggest that lipid changes commence prior to RA diagnosis and that ACPAs might play a role.